Project Grant 2131876

Award Date 1/1/22
Completion Date 12/31/22
Dollars Obligated $256K
Federal Grant Program
47.041
Assistance Type
Project Grant
Place of Performance
Warminster, PA 18974, USA
Similar Awards
The National Science Foundation Division of Industrial Innovation awarded $255,700 to Creative Biotherapeutics LLC through its Engineering program (CFDA 47.041) on January 15, 2021 to fund the project "SBIR PHASE I: STRESS PATHWAY INHIBITION PREVENTS COVID-19 INFECTION (COVID-19)." This Project Grant will support Creative Biotherapeutics' research efforts through December 31, 2021 to develop inhibitors of stress response pathways to prevent COVID-19 infection. The NSF Engineering...
The National Science Foundation awarded a $255,981 Small Business Innovation Research Phase I Project Grant to Frezent Biological Solutions Inc. of Valhalla, NY under the Engineering (CFDA 47.041) federal grant program. The grant funds the development of a novel peptide inhibitor of the coronavirus papain-like protease as a prophylactic and antiviral therapeutic for COVID-19, to be administered via inhalation. The Engineering program seeks to improve quality of life and economic strength...
This Project Grant from the National Science Foundation (NSF) Engineering program (CFDA 47.041) provided $255,943 to Athem LLC from February 15, 2021 through March 31, 2022. The grant funded the development of a medical device to isolate and purify therapeutic antibodies from recovered COVID-19 donors. The NSF Engineering program seeks to improve quality of life and economic strength by fostering innovation and excellence in engineering research. This award aimed to advance those goals by...
The National Science Foundation awarded a $256,000 Small Business Innovation Research Phase I Project Grant to White Rock Therapeutics under the Engineering federal grant program (CFDA 47.041). The grant will support development of an ACE2 decoy as a pan-coronavirus therapeutic from January 2022 to December 2022. The Engineering program seeks to improve quality of life and economic strength by fostering innovation and excellence in engineering research. This award will fund initial research...
This National Science Foundation Project Grant of $255,927 awarded to Invvax, Inc. on March 1, 2022 seeks to develop stable prophylactic antibodies through February 2023. Funded through the NSF Engineering Directorate's CFDA 47.041 program, this Small Business Innovation Research Phase I project will engineer mutations to antibody Fc regions to resist degradation and enhance binding to the neonatal Fc receptor for potentially decades-long duration. Specifically, the awardee will combine known...
Florica Therapeutics, Inc. was awarded a $275,678 Project Grant from the National Science Foundation Division of Industrial Innovation under the Engineering (47.041) federal grant program. The grant will support research from January 15, 2021 through December 31, 2021 to develop hypothalamus stem cell exosomes for the treatment of COVID-19. As part of its mission to improve lives and economic strength through engineering innovation, the NSF Engineering program aims to foster excellence in...
The National Science Foundation (NSF) awarded a $997,689 Cooperative Agreement under its NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Omnicyte LLC, a minority-owned small business in Branford, CT. The funding supports the design and production of a next-generation COVID-19 vaccine that addresses weaknesses of current vaccines, such as reduced booster effectiveness, short-lived efficacy, and side effects. The project aims to develop a vaccine candidate with improved...
Neyroblastgx LLC was awarded a $255,997 Project Grant from the National Science Foundation under the NSF Technology, Innovation, and Partnerships program. The grant will support the company's research efforts to genetically engineer dendritic cells to activate T cells specific to the SARS-CoV-2 spike protein, with the goal of developing a novel approach to treating COVID-19. The research is expected to be conducted between April 2021 and December 2022. The NSF Technology, Innovation, and...
The National Science Foundation awarded Diant Pharma Inc. a $256,000 Project Grant under the Engineering (47.041) federal grant program. The grant will support development of an advanced continuous manufacturing system for nucleic acid lipid nanoparticles to improve supply chains for therapeutics and vaccines. Specifically, the small business innovation research Phase I project aims to create a compact, end-to-end manufacturing platform that follows current good manufacturing practices. This...
The National Science Foundation awarded Fibrosix Inc. a $256,000 Project Grant under the Engineering federal grant program (CFDA 47.041) for the period of March 1, 2021 through August 31, 2021. The grant funding supports Fibrosix's "SBIR PHASE I: QUIETING SYSTEMIC HYPER-INFLAMMATION (COVID-19)" project. Specifically, the grant will enable Fibrosix to conduct research towards developing technologies or techniques to reduce excessive inflammation in response to COVID-19 and future...

The National Science Foundation Division of Industrial Innovation awarded MBF Therapeutics Inc. a $256,000 Project Grant under the Engineering federal grant program (CFDA 47.041) from January 1, 2022 to December 31, 2022.

The grant funds the development of a protective T cell vaccine for SARS CoV-2 (COVID-19). The Engineering program supports innovation, creativity and excellence in engineering research and education to improve quality of life and economic strength. This award furthers those goals by supporting research into a vaccine that could help control the COVID-19 pandemic.

Generated 1/7/24, 7:12 AM